Revenue (Quarterly) Chart

View Revenue (Quarterly) for ORINF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
March 31, 2026 488.68M
December 31, 2025 809.28M
September 30, 2025 493.98M
June 30, 2025 472.79M
March 31, 2025 373.83M
December 31, 2024 463.37M
September 30, 2024 518.18M
June 30, 2024 352.67M
March 31, 2024 335.05M
December 31, 2023 345.32M
September 30, 2023 327.77M
June 30, 2023 314.64M
March 31, 2023 300.42M
December 31, 2022 300.41M
September 30, 2022 495.11M
June 30, 2022 301.93M
March 31, 2022 303.57M
December 31, 2021 316.04M
September 30, 2021 283.95M
June 30, 2021 307.31M
March 31, 2021 323.65M
December 31, 2020 304.49M
September 30, 2020 292.55M
June 30, 2020 322.12M
March 31, 2020 308.36M
Date Value
December 31, 2019 303.91M
September 30, 2019 315.43M
June 30, 2019 282.82M
March 31, 2019 273.65M
December 31, 2018 299.42M
September 30, 2018 257.98M
June 30, 2018 293.07M
March 31, 2018 303.81M
December 31, 2017 313.07M
September 30, 2017 283.44M
June 30, 2017 286.89M
March 31, 2017 282.97M
December 31, 2016 301.63M
September 30, 2016 288.62M
June 30, 2016 308.37M
March 31, 2016 288.86M
December 31, 2015 286.32M
September 30, 2015 265.76M
June 30, 2015 282.09M
March 31, 2015 292.17M
December 31, 2014 318.91M
September 30, 2014 315.71M
June 30, 2014 379.43M
March 31, 2014 335.69M
December 31, 2013 371.08M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 15.26B
ANI Pharmaceuticals, Inc. 237.46M
Corcept Therapeutics, Inc. 164.90M
Assertio Holdings, Inc. 9.933M
Veru, Inc. 0.00